The exposed cohort is described as a consecutive series of patients meeting specific inclusion criteria from a defined clinical setting (La Maddalena Cancer Center). The text states: 'A cohort of consecutive patients requiring intrathecal therapy for cancer pain was prospectively surveyed for a period of 4 years (2003 to 2006). Inclusion criteria were previous trials with at least 3 opioids (multiple switching failure) and 2 routes of administration (including the intravenous one).' This indicates a somewhat representative sample of the average exposed person in the community (i.e., advanced cancer patients unresponsive to systemic opioids), as it is a consecutive series from a specialized cancer center, not a truly random community sample. According to NOS guidance, this qualifies for a star under category 'b' (somewhat representative).

The document describes a single cohort of patients receiving intrathecal treatment, with no mention of a separate non-exposed cohort. The study is a single-arm prospective survey, not a cohort study with an exposed and non-exposed group. Therefore, the criterion 'How was the non-exposed cohort selected?' is not applicable, and no star can be awarded.

The document does not describe how the exposure (intrathecal treatment) was ascertained. The exposure is the intervention itself (intrathecal treatment), and the study describes the treatment protocol in detail (e.g., 'Initial intrathecal morphine dose was calculated from the previous opioid consumption using an oral-intrathecal ratio of 100:1' [P2.L11-L12]). However, the NOS criterion for 'ascertainment of exposure' requires a description of how the exposure status was determined or recorded (e.g., from secure medical records, surgical records, or a structured interview). The document does not state that exposure was ascertained from a secure record, a structured interview, or any other specific method. It only describes the treatment itself. Therefore, the evidence is insufficient to award a star.

Raw response parsing failed. Original content: { "judgment": "star awarded", "scoring_rationale": "The study explicitly states that patients were assessed before starting the intrathecal treatment (T0), and that the outcome of interest (pain a...

Raw response parsing failed. Original content: { "judgment": "no star awarded", "scoring_rationale": "The study does not control for any confounders. It is a single-cohort, before-after study with no comparison group. The document contains no ...

The outcome assessment method is not described as independent blind assessment, record linkage, or validated self-report. The document states that pain and symptom intensities were recorded by the patient using a numerical scale and a symptom scale, and that caregivers were instructed to recognize problems. However, there is no mention of blinding of assessors, independent assessment, or linkage to official registries. The self-report measures are not described as validated, and the assessment of complications is not clearly attributed to a blinded or independent source. Therefore, no star is awarded.

The study explicitly states that patients were followed up to death, which is the ultimate outcome for advanced cancer patients. The follow-up duration is therefore clearly sufficient for the outcome of interest (death). The mean survival time is reported as 71 days (95% CI 41-101), and complete data with adequate follow-up until death were available in 45 of 55 patients. This meets the criterion for a star.

The study explicitly states that complete data with adequate follow-up until death were available in 45 out of 55 patients, yielding a follow-up rate of 81.8% (45/55). This exceeds the 80% threshold commonly used for adequacy. Additionally, the authors describe the reasons for incomplete data in the remaining 10 patients (e.g., discontinuation due to complications, loss to follow-up for those living in other provinces, catheter removal, etc.), which provides transparency about the losses. Although the description does not formally compare characteristics of those lost versus those followed, the explicit statement of adequate follow-up and the detailed reasons for loss suggest that bias from loss to follow-up is unlikely to be substantial. Therefore, a star is awarded.